Treatment of chronic viral hepatitis C in children and adolescents: UK experience

Abdel-Hady, Mona; Bansal, Sanjay; Davison, Suzanne; Brown, M.; Tizzard, Sarah; Mulla, Sohail; Barnes, Eleanor; Davies, Paul; Mieli‐Vergani, Giorgina; Kelly, Déirdre

doi:10.1136/archdischild-2013-304601

Cited by 24 publications

(18 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[42] In particular, even if pain represents a constant concern among health professionals, strategies to reduce pain in HD patients still seem wanting. [42,43] In part this is due to organizational uncertainty about who, the nurse or the physician, is responsible for treating symptoms. [44] Further to these results, healthcare professionals should assess presence of pain in HD patients systematically and propose pharmacological and non-pharmacological solutions to remedy the situation.…”

Section: Discussionmentioning

confidence: 99%

Symptoms and quality of life from patients undergoing hemodialysis in Switzerland

Delmas¹,

Cohen²,

Loiselle

et al. 2017

CNS

View full text Add to dashboard Cite

Background: Dialysis patients experience multiple symptoms impairing their quality of life. A relationship seems to exist between the cultural context and the burden of symptoms. In this study, the prevalence and severity of 30 symptoms and their relationship with quality of life among hemodialysis patients in Switzerland is explored. Methods: A cross-sectional correlation design was used with a convenience sample of 119 patients from five dialysis units. Presence and severity of symptoms were assessed with the Dialysis Symptom Index and quality of life with the WHOQOL-Bref questionnaire. Multivariate linear regressions were used to examine the relationship between the prevalence and severity of symptoms, respectively, and quality of life. T-tests and Fisher's tests were used for the international comparisons. Results: On average, patients reported 10 symptoms and often rated these as "somewhat bothersome". The most frequent were: lack of energy, dry skin, trouble falling asleep, trouble staying asleep, and muscle cramps. Average symptoms prevalence and severity levels were both observed to decrease patients' quality of life, items related to physical health and psychological state having the greatest impact. Prevalence and severity of psychological symptoms and prevalence of sex-related symptoms seem to be influenced by patients' cultural context. Conclusions: These results demonstrate that patients on chronic hemodialysis present several symptoms that affect their quality of life. Healthcare professionals should develop strategies to identify more properly these symptoms, especially sex-related and psychological symptoms.

show abstract

Section: Discussionmentioning

confidence: 99%

Symptoms and quality of life from patients undergoing hemodialysis in Switzerland

Delmas¹,

Cohen²,

Loiselle

et al. 2017

CNS

View full text Add to dashboard Cite

show abstract

“…The antiviral drug ribavirin has been used for treatment of hepatitis C virus (HCV) infection in combination with type I IFN (Abdel-Hady et al, 2014;Bansal et al, 2015). Ribavirin exerts its antiviral effect by inhibiting viral RNA-dependent RNA polymerases (Bougie and Bisaillon, 2003;Maag et al, 2001;Toltzis et al, 1988), inhibiting mRNA cap formation (Goswami et al, 1979), and upregulating genes related to IFN signaling (Feld et al, 2007;Zhang et al, 2003), as well as other mechanisms.…”

Section: Introductionmentioning

confidence: 99%

Ribavirin inhibits Zika virus (ZIKV) replication in vitro and suppresses viremia in ZIKV-infected STAT1-deficient mice

et al. 2017

View full text Add to dashboard Cite

Zika fever, a mosquito-borne infectious disease caused by Zika virus (ZIKV), is an epidemic disease for which no effective therapy has been established. The recent outbreaks of ZIKV in Brazil and French Polynesia have been linked to a considerable increase in the incidence of fetal microcephaly and other diseases such as Guillain-Barre syndrome. Because there is currently no specific therapy or vaccine, the early exploitation of a method to prevent expansion of ZIKV is a high priority. To validate commonly used antiviral drugs, we evaluated the effect of ribavirin, a drug used to treat hepatitis C with interferon-β (IFN-β), on ZIKV replication. In mammalian cells, we observed an inhibitory effect of ribavirin on ZIKV replication and ZIKV-induced cell death without cytotoxic effect. Furthermore, we found that STAT1-deficient mice, which lack type I IFN signaling, were highly sensitive to ZIKV infection and exhibited lethal outcome. Ribavirin abrogated viremia in ZIKV-infected STAT-1-deficient mice. These data suggest that the inhibition of viral RNA-dependent RNA polymerases may be effective for treatment of ZIKV infection. Our data provide a new insight into the mechanisms for inhibition of ZIKV replication and prevention of Zika fever.

show abstract

“…Previous studies on pediatric HCV-infected patients found 83% and 86.3% of SVR rate [11,12]. A recent study from UK found that 76% of pediatric patients with CHC who received Peg-IFN and RBV achieved SVR [13]. The reason for the higher SVR rate can be due to the minimal liver fibrosis in the children.…”

Section: Discussionmentioning

confidence: 96%

High Response Rate to Pegylated Interferon Alpha and Ribavirin Combination Therapy in Hemophilic Children with Chronic Hepatitis C; A Case-Control Study

Mehrnoush

Alavian

Sharafi

et al. 2015

Pediatric Hematology and Oncology

View full text Add to dashboard Cite

Scarce data is available on the efficacy of Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) combination therapy in hemophilic children with chronic hepatitis C. The aim of this study was to evaluate the efficacy of Peg-IFN and RBV combination therapy for hemophilic children infected with hepatitis C virus (HCV) in comparison with adult hemophilic patients with chronic hepatitis C. A case-control study comprised 31 pediatric hemophilic patients ages under 16 years with previously untreated HCV genotype-1 or -3 infection as the case group and 62 treatment naive adult hemophilic patients with chronic HCV infection as the control group. Case and control groups were matched case by case according to HCV genotype, HCV RNA level and rs12979860 polymorphism. All patients in the case and control groups were treated with Peg-IFN and RBV for 24-48 weeks according to HCV genotype. Sustained virological response (SVR) was achieved in 26 (83.9%) pediatric patients and in 39 (62.9%) of adult patients (P = 0.05, OR = 3.07, 95%CI = 1.03-9.09). The rate of SVR was not different according to HCV genotype, HCV RNA level, and rs12979860 polymorphism in both studied groups whereas achieving early virological response was associated with achievement of SVR in both groups. The efficacy of Peg-IFN and RBV combination therapy in hemophilic children with chronic hepatitis C is higher than that of adult hemophilic patients.

show abstract

Treatment of chronic viral hepatitis C in children and adolescents: UK experience

Abstract: Children respond well to therapy for CHC. Treatment was tolerated with minimal impact on QoL and no significant effect on growth. Knowledge of viral and IL28 genotypes and early viral response is useful to plan treatment in children and provide appropriate counselling.

Cited by 24 publications

References 36 publications

Symptoms and quality of life from patients undergoing hemodialysis in Switzerland

Symptoms and quality of life from patients undergoing hemodialysis in Switzerland

Ribavirin inhibits Zika virus (ZIKV) replication in vitro and suppresses viremia in ZIKV-infected STAT1-deficient mice

High Response Rate to Pegylated Interferon Alpha and Ribavirin Combination Therapy in Hemophilic Children with Chronic Hepatitis C; A Case-Control Study

Contact Info

Product

Resources

About